AUMEZGO Trademark

Trademark Overview


On Monday, August 2, 2021, a trademark application was filed for AUMEZGO with the United States Patent and Trademark Office. The USPTO has given the AUMEZGO trademark a serial number of 90860808. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Monday, July 29, 2024. This trademark is owned by Celgene Corporation. The AUMEZGO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pha...
aumezgo

General Information


Serial Number90860808
Word MarkAUMEZGO
Filing DateMonday, August 2, 2021
Status732 - THIRD EXTENSION - GRANTED
Status DateMonday, July 29, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 6, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, September 28, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Trademark Events


Event DateEvent Description
Monday, May 2, 2022NON-FINAL ACTION E-MAILED
Monday, May 2, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, August 5, 2021NEW APPLICATION ENTERED
Tuesday, September 28, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, April 29, 2022ASSIGNED TO EXAMINER
Monday, May 2, 2022NON-FINAL ACTION WRITTEN
Thursday, October 27, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, October 27, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, October 27, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, October 28, 2022EXAMINERS AMENDMENT -WRITTEN
Friday, October 28, 2022EXAMINERS AMENDMENT E-MAILED
Friday, October 28, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, October 28, 2022EXAMINER'S AMENDMENT ENTERED
Friday, October 28, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, December 6, 2022PUBLISHED FOR OPPOSITION
Wednesday, November 16, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 6, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 31, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, July 13, 2023SOU TEAS EXTENSION RECEIVED
Friday, January 5, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 29, 2024SOU TEAS EXTENSION RECEIVED
Monday, July 29, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 29, 2024SOU EXTENSION 3 FILED
Monday, July 29, 2024SOU EXTENSION 3 GRANTED
Wednesday, January 3, 2024SOU EXTENSION 2 GRANTED
Thursday, July 13, 2023SOU EXTENSION 1 FILED
Thursday, July 13, 2023SOU EXTENSION 1 GRANTED
Saturday, July 15, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 3, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, January 3, 2024SOU EXTENSION 2 FILED